15 research outputs found
Аліментні обов'язки інших членів сім'ї та родичів
Виявлено проблеми у врегулюванні аліментних обов’язків інших членів сім’ї та родичів, вироблено рекомендації щодо їх вирішення. Проаналізовано специфіку правового
регулювання аліментних зобов’язань зазначених суб’єктів, сімейне законодавство та
міжнародний досвід.
Ключові слова: аліментні обов’язки, правове регулювання, сімейне законодавство.Выявлены проблемы в урегулировании алиментных обязанностей других членов семьи и родственников, выработаны рекомендации по их решению. Проанализирована
специфика правового регулирования алиментных обязательств указанных субъектов,
семейное законодательство и международный опыт.
Ключевые слова: алиментные обязанности, правовое регулирование, семейное законодавствоThis article is dedicated to identifying problems in the regulation of the alimentary obligations of other family members and relatives, and to making recommendations and proposing solutions. Studing the specificity of the legal regulation of alimentary obligations of these
entities, analysing the current family law and international experience are very important.
Key words: alimentary obligations, legal regulation, family law
Impact of nationwide enhanced implementation of best practices in pancreatic cancer care (PACAP-1): A multicenter stepped-wedge cluster randomized controlled trial
Background: Pancreatic cancer has a very poor prognosis. Best practices for the use of chemotherapy, enzyme replacement therapy, and biliary drainage have been identified but their implementation in daily clinical practice is often suboptimal. We hypothesized that a nationwide program to enhance implementation of these best practices in pancreatic cancer care would improve survival and quality of life. Methods/design: PACAP-1 is a nationwide multicenter stepped-wedge cluster randomized controlled superiority trial. In a per-center stepwise and randomized manner, best practices in pancreatic cancer care regarding the use of (neo)adjuvant and palliative chemotherapy, pancreatic enzyme replacement therapy, and metal biliary stents are implemented in all 17 Dutch pancreatic centers and their regional referral networks during a 6-week initiation period. Per pancreatic center, one multidisciplinary team functions as reference for the other centers in the network. Key best practices were identified from the literature, 3 years of data from existing nationwide registries within the Dutch Pancreatic Cancer Project (PACAP), and national expert meetings. The best practices follow the Dutch guideline on pancreatic cancer and the current state of the literature, and can be executed within daily clinical practice. The implementation process includes monitoring, return visits, and provider feedback in combination with education and reminders. Patient outcomes and compliance are monitored within the PACAP registries. Primary outcome is 1-year overall survival (for all disease stages). Secondary outcomes include quality of life, 3- and 5-year overall survival, and guideline compliance. An improvement of 10% in 1-year overall survival is considered clinically relevant. A 25-month study duration was chosen, which provides 80% statistical power for a mortality reduction of 10.0% in the 17 pancreatic cancer centers, with a required sample size of 2142 patients, corresponding to a 6.6% mortality reduction and 4769 patients nationwide. Discussion: The PACAP-1 trial is designed to evaluate whether a nationwide program for enhanced implementation of best practices in pancreatic cancer care can improve 1-year overall survival and quality of life. Trial registration: ClinicalTrials.gov, NCT03513705. Trial opened for accrual on 22th May 2018
Early biliary decompression versus conservative treatment in acute biliary pancreatitis (APEC trial): study protocol for a randomized controlled trial
Excipients in the Paediatric Investigation Plans (n = 150); group wise comparison.
<p>*a preparation is a subtype of a dosage form in a particular strength and with a particular excipient composition.</p>%<p>excipient that has raised special attention by regulators in recent years due to a non-confirmed safety signal.</p>&<p>studied by McCann et al. in the Southampton study and considered as potentially harmful <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0098348#pone.0098348-McCann1" target="_blank">[18]</a>. The study conclusion was questioned by EFSA <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0098348#pone.0098348-Scientific1" target="_blank">[19]</a>.</p>#<p>may be used as a safe(r) alternative to the colourants studied by McCann et al. <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0098348#pone.0098348-McCann1" target="_blank">[18]</a>.</p
Oral medicines in the Paediatric Investigation Plans (n = 150 PIPs); group wise comparison.
<p>*a preparation is a subtype of a dosage form in a particular strength and with a particular excipient composition e.g. a PIP containing film-coated tablets 50 mg and chewable tablets 5, 10 and 20 mg represents one overall dosage form (tablets), two tablet subtype dosage forms (film-coated tablets and chewable tablets) and four preparations (film-coated tablets 50 mg, chewable tablets 5 mg, chewable tablets 10 mg, chewable tablets 20 mg).</p
Oral preparations in the PIPs per target age group.
<p>Oral preparations in the PIPs per target age group.</p
Tablet size and shape (n = 150 PIPs); group wise comparison children aged between 2 and 6 years.
<p>*tablets counted as the number of oral preparations i.e. differentiated to excipient composition and strength. A small tablet wa defined as 0–4 mm, medium sized 5–9 mm and large 10 mm or larger <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0098348#pone.0098348-European8" target="_blank">[21]</a>. Oval tablets included those that were oblong or capsule shaped.</p>&<p>related to the two tablets sized 10 mm or larger.</p
Oral medicines for children in the European paediatric investigation plans
INTRODUCTION: Pharmaceutical industry is no longer allowed to develop new medicines for use in adults only, as the 2007 Paediatric Regulation requires children to be considered also. The plans for such paediatric development called Paediatric Investigation Plans (PIPs) are subject to agreement by the European Medicines Agency (EMA) and its Paediatric Committee (PDCO). The aim of this study was to evaluate the key characteristics of oral paediatric medicines in the PIPs and the changes implemented as a result of the EMA/PDCO review. METHODS: All PIPs agreed by 31 December 2011 were identified through a proprietary EMA-database. PIPs were included if they contained an agreed proposal to develop an oral medicine for children 0 to 11 years. Information on the therapeutic area (EMA classification system); target age range (as defined by industry) and pharmaceutical characteristics (active substance, dosage form(s) as listed in the PIP, strength of each dosage form, excipients in each strength of each dosage form) was extracted from the EMA website or the EMA/PDCO assessment reports. RESULTS: A hundred and fifty PIPs were included corresponding to 16 therapeutic areas and 220 oral dosage forms in 431 strengths/compositions. Eighty-two PIPs (37%) included tablets, 44 (20%) liquids and 35 (16%) dosage forms with a specific composition/strength that were stored as a solid but swallowed as a liquid e.g. dispersible tablets. The EMA/PDCO review resulted in an increase of 13 (207 to 220) oral paediatric dosage forms and 44 (387 to 431) dosage forms with a specific composition/strength. For many PIPs, the target age range was widened and the excipient composition and usability aspects modified. CONCLUSION: The EMA/PDCO review realized an increase in the number of requirements for the development of oral dosage forms and a larger increase in the number of dosage forms with a specific composition/strength, both targeting younger children. Changes to their pharmaceutical design were less profound
PIPs including at least one oral medicine for children 0–11 years.
<p>PIPs including at least one oral medicine for children 0–11 years.</p